Illumina completes its $350M acquisition of SomaLogic, expanding its multiomics portfolio with scalable proteomics technology to accelerate drug discovery and advance precision health care.
Written By: Pharmacally Medical News Desk
Illumina, Inc. has finalized its acquisition of SomaLogic, advancing its strategy to expand from genomics into large-scale proteomics and multiomics solutions. Announced as a key milestone, the deal integrates SomaLogic’s data-driven proteomics platform with Illumina’s sequencing expertise, enabling deeper protein biology insights.
Strategic Fit and Multiomics Expansion
The acquisition bolsters Illumina’s multiomics portfolio by combining proteomic data with genomic information. This synergy aims to speed drug discovery, enhance disease understanding, and drive precision medicine.
Illumina CEO Jacob Thaysen highlighted the move as a cornerstone of the company’s vision. “Combining SomaLogic’s differentiated proteomics technology with Illumina’s innovation and global reach will deliver scalable multiomic insights for better patient outcomes,” he said.
SomaScan Technology and Integrated Tools
SomaLogic’s flagship SomaScan platform measures thousands of proteins at scale, providing comprehensive proteomic profiling. Customers now gain access to an enhanced ecosystem, including:
- SomaScan proteomics assays
- Illumina Protein Prep workflows
- SomaSignal diagnostic tests
- DRAGEN bioinformatics software
- Illumina Connected Multiomics platform
These tools generate richer datasets from limited samples, offering workflow flexibility for researchers.
Market Growth and Collaboration History
The deal positions Illumina for expansion in the booming proteomics market while complementing its high-throughput sequencing leadership. The companies collaborated since late 2021 on a co-development agreement, adapting SomaScan for Illumina’s sequencing platforms. This acquisition builds directly on that foundation.
Deal Terms and Next Steps
Illumina acquired SomaLogic and select assets from Standard BioTools for $350 million in cash, plus up to $75 million in performance milestones and royalties funded by cash reserves. Full financial details will follow in Illumina’s February 5, 2026, earnings call.
Illumina commits to seamless continuity for SomaLogic customers, integrating the portfolio into its roadmap while honoring existing partnerships and services.
References
Illumina completes acquisition of SomaLogic, 30 January 2026, https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b7bf54f5-b534-47b4-a629-02ade3b10178